DNLI Denali Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DNLI

Price (delayed)

$24.1

Market cap

$3.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$3.43B

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing ...

Highlights
The EPS has soared by 68% YoY and by 12% from the previous quarter
The net income has soared by 63% year-on-year and by 5% since the previous quarter
Denali Therapeutics's gross profit has surged by 191% YoY but it has decreased by 11% QoQ
DNLI's revenue has soared by 191% year-on-year but it is down by 11% since the previous quarter
The quick ratio has declined by 15% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.denalitherapeutics.com
Peers: NVCR NVAX

Key stats

What are the main financial stats of DNLI
Market
Shares outstanding
142.61M
Market cap
$3.44B
Enterprise value
$3.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.3
Price to sales (P/S)
12.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.6
Earnings
Revenue
$295.39M
EBIT
-$137.22M
EBITDA
-$128.37M
Free cash flow
-$425.11M
Per share
EPS
-$0.93
Free cash flow per share
-$2.85
Book value per share
$10.46
Revenue per share
$1.98
TBVPS
$10.58
Balance sheet
Total assets
$1.58B
Total liabilities
$125.62M
Debt
$50.55M
Equity
$1.46B
Working capital
$890.99M
Liquidity
Debt to equity
0.03
Current ratio
11.79
Quick ratio
11.34
Net debt/EBITDA
0.08
Margins
EBITDA margin
-43.5%
Gross margin
100%
Net margin
-46.5%
Operating margin
-65.5%
Efficiency
Return on assets
-10.4%
Return on equity
-11.5%
Return on invested capital
-11.6%
Return on capital employed
-9.2%
Return on sales
-46.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DNLI stock price

How has the Denali Therapeutics stock price performed over time
Intraday
0.04%
1 week
12.3%
1 month
9.55%
1 year
-13.56%
YTD
12.3%
QTD
3.79%

Financial performance

How have Denali Therapeutics's revenue and profit performed over time
Revenue
$295.39M
Gross profit
$295.39M
Operating income
-$193.6M
Net income
-$137.25M
Gross margin
100%
Net margin
-46.5%
Denali Therapeutics's gross profit has surged by 191% YoY but it has decreased by 11% QoQ
DNLI's revenue has soared by 191% year-on-year but it is down by 11% since the previous quarter
Denali Therapeutics's net margin has soared by 87% YoY but it has decreased by 6% from the previous quarter
DNLI's operating margin has surged by 83% year-on-year but it is down by 10% since the previous quarter

Growth

What is Denali Therapeutics's growth rate over time

Valuation

What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
2.3
P/S
12.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.6
The EPS has soared by 68% YoY and by 12% from the previous quarter
Denali Therapeutics's equity has surged by 51% YoY and by 41% QoQ
DNLI's price to book (P/B) is 50% less than its 5-year quarterly average of 4.6 and 15% less than its last 4 quarters average of 2.7
DNLI's revenue has soared by 191% year-on-year but it is down by 11% since the previous quarter
The stock's price to sales (P/S) is 72% less than its 5-year quarterly average of 43.1 but 23% more than its last 4 quarters average of 9.9

Efficiency

How efficient is Denali Therapeutics business performance
The ROS has soared by 87% YoY but it has decreased by 6% from the previous quarter
The return on invested capital has surged by 72% year-on-year and by 15% since the previous quarter
The return on equity has surged by 71% year-on-year and by 15% since the previous quarter
The return on assets has surged by 62% year-on-year and by 9% since the previous quarter

Dividends

What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNLI.

Financial health

How did Denali Therapeutics financials performed over time
DNLI's total liabilities has dropped by 72% year-on-year but it is up by 2.2% since the previous quarter
The company's total assets rose by 37% QoQ and by 12% YoY
Denali Therapeutics's debt is 97% less than its equity
Denali Therapeutics's equity has surged by 51% YoY and by 41% QoQ
DNLI's debt to equity has dropped by 50% year-on-year and by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.